文献速递药物相互作用

HDI Highlighter:首个智能筛查草药-药物相互作用文献的工具

HDI Highlighter, The First Intelligent Tool to Screen the Literature on Herb-Drug Interactions.
PubMed 文献 · Clin Pharmacokinet · 2022-05-31

草药食品补充剂使用普遍且存在获益/风险平衡,可能与其他治疗发生相互作用。研究团队开发了名为「HDI Highlighter」的阅读辅助工具,利用自然语言处理算法(人工智能)从生物医学文献中提取草药-药物相互作用的关键信息,并测试了120篇近10年发表的文章。该工具可快速概览草药-药物相互作用文献,但病例报告常缺乏对草药的严谨描述,临床研究患者数量有限,使解读复杂化。

要点

  • HDI Highlighter利用自然语言处理算法辅助筛选草药-药物相互作用文献。
  • 病例报告常涉及肿瘤、HIV、抗癫痫药或中枢神经系统药物等长期治疗。
  • 病例报告常缺乏对所用草药的严谨描述,临床研究患者数量有限。

核心结论

  • HDI Highlighter可快速概览草药-药物相互作用文献,但现有文献的局限性使解读复杂。

研究设计与样本

  • 研究开发了名为「HDI Highlighter」的阅读辅助工具,使用以药学为重点的自然语言处理算法(人工智能)进行语义关系提取,并测试回顾了120篇近10年发表的文章。

主要发现

  • 病例报告常涉及长期或半长期治疗,如肿瘤或人类免疫缺陷病毒治疗、抗癫痫药物或中枢神经系统药物。
  • 上述药物类别在临床研究中也被更广泛地 targeting。
  • 病例报告中描述的草药-药物相互作用涉及药用、娱乐性和食用用途。
  • 病例报告通常缺乏对所用草药的严谨描述。
  • 临床研究通常提供完整的方案和剂量描述,少数例外由患者需求解释。

临床怎么用

  • 临床药学人员可用该工具快速筛查草药-药物相互作用相关文献,辅助识别关键信息。
  • 解读病例报告中的草药-药物相互作用时需注意草药描述可能不严谨。
  • 参考临床研究时需注意其患者数量有限的局限性。

局限性

  • 病例报告通常缺乏对草药的严谨描述。
  • 临床研究患者数量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Herbal food supplements are commonly used and can be an important part of patient self-care. Like all other bio-active and therapeutic products, they have a benefit/risk balance. These products are not without adverse effects and potentially interact with other therapies. Educating patients and providing information for health professionals about the risk of herb-drug interactions is key. One of the purposes of the biomedical literature is to inform prescribers. Scientific literature accessible on databases such as PubMed is dense and careful reading is time consuming. We propose a reading aid tool named "HDI highlighter" to help readers to find key information in clinical studies and case reports describing herb-drug interactions. It uses natural language processing algorithms (artificial intelligence) with a pharmaceutical focus. Semantic relation extraction for herb-drug interactions from the biomedical literature are overexpressed using keywords. We have tested it to review 120 published articles over the last 10 years. In these articles, we have shown that case reports often involved long-term or semi-long-term treatments such as cancer or human immunodeficiency virus therapies, antiepileptic drugs, or central nervous system drugs. Similarly, these classes of drugs are more extensively targeted by clinical studies. Herb-drug interactions described in case reports are identified in medicinal, recreational, and alimentary uses. They also usually lack a rigorous description of the herb(s) involved. Typically, clinical studies provide a complete description of protocols and dosages, with a few exceptions explained by patients' needs. Clinical studies on herbs are nevertheless conducted on a limited number of patients. All these limitations make the interpretation of herb-drug interactions complicated, but the HDI highlighter provides a quick overview of the herb-drug interaction literature.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Cnudde A, Watrin P, Souard F, et al. HDI Highlighter, The First Intelligent Tool to Screen the Literature on Herb-Drug Interactions. Clin Pharmacokinet. 2022. PMID: 35637377. doi:10.1007/s40262-022-01131-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。